Lava Therapeutics Nv (LVTX)
$1.73
+0.05
(+2.98%)▲
Live
Performance
- $1.70$1.78$1.73
1.73%
Downside
Day's Volatility :4.49%
Upside
2.81%
- $1.13$6.47$1.73
34.62%
Downside
52 Weeks Volatility :82.52%
Upside
73.26%
Returns
| Period | Lava Therapeutics Nv | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -16.83% | 3.6% | 0.0% |
6 Months | -41.05% | 10.2% | 0.0% |
1 Year | 21.74% | 19.6% | 0.0% |
3 Years | -76.5% | 16.8% | -23.0% |
Highlights
Market Capitalization | 43.4M |
Book Value | $1.63 |
Earnings Per Share (EPS) | -0.89 |
Wall Street Target Price | 7.25 |
Profit Margin | 0.0% |
Operating Margin TTM | -371.48% |
Return On Assets TTM | -15.99% |
Return On Equity TTM | -45.3% |
Revenue TTM | 7.4M |
Revenue Per Share TTM | 0.27 |
Quarterly Revenue Growth YOY | 471.2% |
Gross Profit TTM | -20.7M |
EBITDA | -26.9M |
Diluted Eps TTM | -0.89 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.14 |
EPS Estimate Next Year | -1.94 |
EPS Estimate Current Quarter | -0.36 |
EPS Estimate Next Quarter | -0.38 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 319.08%
Technicals Summary
Sell
Neutral
Buy
Lava Therapeutics Nv is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Lava Therapeutics Nv | 3.07% | -41.05% | 21.74% | -76.5% | -88.25% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Lava Therapeutics Nv | 0.25 | NA | NA | -1.14 | -0.45 | -0.16 | NA | 1.63 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Lava Therapeutics Nv | Buy | $43.4M | -88.25% | 0.25 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Lava Therapeutics Nv
Decreasing Revenue
Revenue is down for the last 2 quarters, 6.99M → 227.99K (in $), with an average decrease of 96.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -553.0K → -8.29M (in $), with an average decrease of 1400.2% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 58.5%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 121.3%
Institutional Holdings
Redmile Group, LLC
7.89%Bruce & Co Inc
2.94%Sphera Funds Management Ltd.
1.40%Two Sigma Investments LLC
0.43%Pathway Financial Advisors LLC
0.39%Alpha Wave Global LP
0.33%
Company Information
Organization | Lava Therapeutics Nv |
Employees | 37 |
CEO | Mr. Stephen Allen Hurly M.B.A., M.Sc. |
Industry | Services |
